Semprus Biosciences Corp. closes an $18 million Series B funding round, which CEO David Lucchino says it will use to build out its management team and fund manfuacturing ramp-up for its nanotech catheter coating.
Semprus BioSciences Corp. reeled in $18 million in Series B financing for its nanotech medical device coating.
Semprus CEO David Lucchino told MassDevice that the company will use the proceeds to build a team of "been there, done that" medical device executives and to scale up its manufacturing operations.
"Investor expectations with this round of funding are that we would gain regulatory and clinicial clarity, along with having an initial product in hand to start initial sales. We're looking at the next 24 months as being that window," Lucchino told us.
The FDA approves Eos Imaging's hipEos 3D software for planning hip replacement surgeries.
Intravascular imaging company Infraredx files for an initial public offering worth $55 million.
Abbott says it closed the $250 million buyout of Topera Medical and its cardiac arrhythmia mapping...
Medtronic touts a new study showing that its In.Pact Admiral drug-eluting balloon performed better...